sugarBEAT® is a non-invasive and flexible continuous glucose monitor (CGM) providing actionable insights derived from real time glucose measurements and daily glucose trend data, which … 20h globenewswire.com - LOUGHBOROUGH, England, Dec. 11, 2020 (GLOBE NEWSWIRE) - Nemaura Medical, Inc. (NASDAQ: NMRD)(“Nemaura” or the “Company”), a medical technology company focused on developing and commercializing non-invasive wearable diagnostic devices and supporting personalized lifestyle coaching programs, today announces announces that CEO Dr. Faz Chowdhury … Interactive Chart for Nemaura Medical Inc. (NMRD), analyze all the data with a huge range of indicators. Dr. Faz Chowdhury, Nemaura Medical’s Chief Executive Officer stated, “We are delighted and honored to be working with Healthimation to bring diabetic patients an easy-to-use solution that combines our proBEAT™ CGM product with a clinically validated diabetes management and reversal program. We believe this is the first device of its kind on the market and will provide users with an unprecedented, personalized set of tools designed to help reduce diabetes risk and even potentially reverse Type 2 diabetes with continued and dedicated use,” commented Dr. Faz Chowdhury, Nemaura’s Chief Executive Officer. UK-based Nemaura Medical’s CEO Dr Faz Chowdhury explains, “We see a significant commercial opportunity to utilize our Beat platform technology specifically for CTM purposes with data being automatically sent by low energy Bluetooth to a mobile phone app from which it can then be reviewed by the user and/or sent to a family member or caregiver. Exhibit 99.1 . Dr. Faz Chowdhury, Nemaura Medical’s Chief Executive Officer commented, “We are very pleased to welcome Justin to Nemaura. ... allowing more patients to be empowered with CGM data,” Nemaura CEO Dr. Faz Chowdhury told us. Nemaura’s CEO, Dr. Faz Chowdhury, commented, “The USA represents the largest single market for sugarBEAT® and submission of the PMA application is a major milestone for the Company. Tax Planning; Personal Finance; Save for College; Save for Retirement; Invest in Retirement Nemaura Medical Announces Interview with CEO to Air on May 11. The medical technology company is in the midst of commercializing sugarBEAT, a non-invasive and flexible continuous glucose monitor (CGM) for diabetes management. Dr. Faz Chowdhury, CEO of Nemaura Medical, said: “We are very pleased and revered by the paintings with Healthimation to provide diabetic patients with an easy-to-use solution that combines our proBEAT ™ CGM product with a clinically validated diabetes control and reversal program. Yep, that’s the promise of the new SugarBEAT CGM from UK-based Nemaura Medical. ET. Dr. Faz Chowdhury, CEO of Nemaura Medical, stated, “We are very pleased to have commenced the first phase of our commercial launch. CEO Dr. Faz Chowdhury will be participating in an investor webinar, hosted by RedChip Companies, on Tuesday, July 7, 2020 at 11:00 a.m. A live Q&A session with Dr. Chowdhury will follow the presentation. Nemaura CEO Dr Faz Chowdhury said: “We highly value Dr Wessling’s expertise and strategic industry insight built over 30 years with LTS, and his extensive network will support our ambitious plans for expansion and growth. Nemaura Medical Inc (NASDAQ:NMRD) CEO Dr Faz Chowdhury will give investors new insights into its sugarBEAT study in an interview with RedChip Companies on May 11.. ET. Faz Chowdhury is the Chief Executive Officer of Nemaura Pharma (Loughborough, UK), a pharmaceutical drug-delivery company developing patented formulation technologies alongside transdermal systems. RedChip’s exclusive interview with Dr. Faz Chowdhurry, CEO of Nemaura Medical (NASDAQ: NMRD). The U.S. has about 30 million individuals with Type 2 diabetes and an estimated 88 million pre-diabetics, according to the Centers for Disease Control and Prevention, or CDC. Nemaura Medical Inc (NASDAQ:NMRD) CEO Dr Faz Chowdhury will give investors new insights into its sugarBEAT study in an interview with RedChip Companies on May 11. Nemaura Medical Inc Health, Wellness and Fitness Loughborough, United Kingdom 385 followers Innovative, R&D-led patented biomedical diagnostic technologies. The medical technology company is in the midst of commercializing sugarBEAT, a non-invasive and flexible continuous glucose monitor (CGM) for diabetes management. Nemaura’s Chief Executive Officer Dr. Faz Chowdhury will give a presentation titled “CGM Usage for the Management and Reversal of Type 2 diabetes.” Due to the impact of COVID-19, the 20th Annual Diabetes Technology Meeting will be held as a virtual event. A live Q&A session with Dr. Chowdhury … Nemaura Medical, Inc. (NASDAQ: NMRD) ("Nemaura" or the "Company"), a medical technology company focused on developing micro-systems-based wearable diagnostic devices and currently commercializing sugarBEAT®, its non-invasive and flexible continuous glucose monitor ("CGM"), together with BEAT™diabetes, a planned health subscription service designed to help people with Type 2 … Dr. Faz Chowdhury, CEO of Nemaura Medical, commented, “The GCC Region is a key market for SugarBEAT® because the prevalence of diabetes is one of the highest in the world. Having originally trained as a pharmaceutical scientist, Dr Chowdhury received his PhD in Nanomedicine from the University of Oxford (Oxford, UK). Nemaura Secures $5 Million Loan to Accelerate Commercial Strategy . Nemaura Medical Inc. (NMRD) is a medical technology company developing micro-systems-based wearable diagnostic devices and currently commercializing sugarBEAT® and BEAT®diabetes. We are delighted to be involved with TPMENA, which brings an extensive network and proven track record. LOUGHBOROUGH, England, Oct. 22, 2020 (GLOBE NEWSWIRE) -- Nemaura Medical, Inc ... Nemaura’s Chief Executive Officer Dr. Faz Chowdhury will give … Nemaura Medical Inc (NASDAQ:NMRD) CEO Dr Faz Chowdhury said Tuesday the company plans “to take full advantage” of the opportunity to commercialize in the US its non-invasive continuous glucose monitor sugarBEAT for patients with Type 2 diabetes. Dr Faz Chowdhury, CEO of Nemaura Medical commented "We are pleased to announce our uplist to the OTC Quote Board, which we expect will enhance our … Nemaura is a medical technology company developing SugarBEAT® as a non-invasive, affordable and flexible Continuous Glucose Monitor (CGM) designed to help people with diabetes and pre-diabetics better manage their glucose levels by spending more time in range. CEO Dr. Faz Chowdhury will be participating in an investor webinar, hosted by RedChip Companies, on Tuesday, July 7, 2020 at 11:00 a.m. Nemaura’s CEO, Dr. Faz Chowdhury, commented, “The USA represents the largest single market for sugarBEAT® and submission of the PMA application is a major milestone for the Company. “This is a major milestone in Nemaura’s history, giving us an immediate foray into the world’s largest single market,” said Dr. Faz Chowdhury, Nemaura’s CEO.